Effect of a spatial repellent on malaria incidence in an area of western Kenya characterised by high malaria transmission, insecticide resistance, and universal coverage of insecticide treated nets (part of the AEGIS Consortium): a cluster-randomised, controlled trial.
Ochomo EO, Gimnig JE, Awori Q, Abong'o B, Oria P, Ashitiba NK, Polo B, Moshi V, Otanga H, Adung'o F, Ouma EA, Outa S, Ramaita E, Levine R, Odongo W, Harvey SA, Monroe A, Hudson A, Sandberg B, Hendrickson J, Zhao X, Zhou R, Liu F, Achee NL, Grieco JP
- DOI
- 10.1016/S0140-6736(24)02253-0
- Record issued
- 2026-08-16
- Engine
- 7.39.0
- Exported
- 2026-09-21
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/46bef618-94b6-4e06-81ea-1a0e775e90f9 is authoritative.
How this rating was calculated
- IntegrityIntegrity concern−0.5★
- ReportingData & code availability partially met−0.25★
- The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 32 reported means were read, and their group size is not stated where the values are printed. These checks need the count the mean was averaged over, so none was performed.
- No data or code availability links were detected to verify.
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted cluster-randomized controlled trial with rigorous design, clear reporting, and appropriate ethical approvals. The main weakness is the vague data availability statement, which lacks a concrete repository or access mechanism.
Both reviewers classified the study as interventional; no divergence. The statistics verification covered only 2 tests (limited coverage), and the citation check found no retracted or missing references. The copyedit pass flagged minor issues including a missing figure reference and inconsistent notation.
Numerical inconsistencies
1 finding · worst lowValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.
- CONSISTENTreported p = .006 · recomputed p = .006Reviewers 1, 2Recompute two-sided p-value for primary endpoint at interim from reported hazard ratio and 95% CI.
“The estimated protective efficacy of spatial repellents against first-time malaria infection relative to placebo from the intention-to-treat cohort population (cluster core areas) at the interim timepoint () was 33·4% (95% two-sided CI 11·1–50·1; one-sided p=0·0029 and two-sided p=0·0058).”
Taken as given: The hazard ratio is 0.67 (from Table 2).; The 95% CI is (0.50, 0.89) (from Table 2).; The p-value is two-sided.Method: Used pCI function with log=1 for hazard ratio.How we recomputed it: pCI(0.666, 0.499, 0.889, 1) - CONSISTENTreported p = .003 · recomputed p = .003Reviewers 1, 2Recompute two-sided p-value for primary endpoint at final from reported hazard ratio and 95% CI.
“The estimated protective efficacy of spatial repellents against first-time malaria infection from the intention-to-treat cohort population based on final data () to the trial’s end was 32·7% (95% CI 12·6–48·2; one-sided p=0·0015 and two-sided p=0·0030).”
Taken as given: The hazard ratio is 0.67 (from Table 2).; The 95% CI is (0.52, 0.87) (from Table 2).; The p-value is two-sided.Method: Used pCI function with log=1 for hazard ratio.How we recomputed it: pCI(0.673, 0.518, 0.874, 1)
- lowinternal contradictionThe abstract reports a protective efficacy of 33.4% for the primary endpoint, while the final data analysis reports 32.7%. This is not a contradiction but a difference between interim and final analyses.
The outcome of the primary endpoint indicated that spatial repellents significantly reduced the hazard rate of first-time malaria infection by 33·4% (95% CI 11·1–50·1; p=0·0058) ... The estimated protective efficacy of spatial repellents against first-time malaria infection from the intention-to-treat cohort population based on final data () to the trial’s end was 32·7% (95% CI 12·6–48·2; one-sided p=0·0015 and two-sided p=0·0030).
Abstractreviewer’s wording
Overstated conclusions
1 finding · worst lowConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Conclusions only partially backed by the presented evidenceAssessed
6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.
- partialReviewer 1Spatial repellents might offer benefit in neighbouring villages at high coverage.The diversion analysis showed a reduction in buffer zones, but the claim of benefit to neighbours is an inference from secondary endpoints.Evidence: Diversion effect analysis showed reduced infections in buffer zones.
“The reduction in incidence observed in neighbouring villages indicates that at high coverage, spatial repellents might offer benefit, as has been observed previously in trials of ITNs.”
Discussion ¶5Find in source - supportedReviewers 1, 2Spatial repellents significantly reduced the hazard rate of first-time malaria infection by 33.4%.The reported hazard ratio and confidence interval support this claim.Evidence: Interim analysis: protective efficacy 33.4% (95% CI 11.1-50.1, p=0.0058).
“The outcome of the primary endpoint indicated that spatial repellents significantly reduced the hazard rate of first-time malaria infection by 33·4% (95% CI 11·1–50·1; p=0·0058)”
AbstractFind in source - supportedReviewers 1, 2Spatial repellents reduced the hazard rate of overall new malaria infections by 32.1%.The reported effect size and confidence interval support this claim.Evidence: Interim analysis: protective efficacy 32.1% (95% CI 15.9-45.2, p=0.0004).
“the hazard rate of overall new malaria infections by 32·1% (15·9–45·2; p=0·0004)”
AbstractFind in source - supportedReviewers 1, 2No reported adverse events and serious adverse events were deemed to be associated with the spatial repellent.The paper reports no associated adverse events, consistent with the claim.Evidence: Results section states no adverse events were deemed associated.
“No reported adverse events and serious adverse events were deemed to be associated with the spatial repellent.”
AbstractFind in source - supportedReviewers 1, 2This trial provides the first evidence of a demonstrative spatial repellent protective efficacy in reducing risk of malaria infection in an African setting.The paper's literature search found no prior cluster-RCT in Africa, supporting the novelty claim.Evidence: Research in context section states no existing outcomes from a cluster-RCT in Africa.
“Our trial provides the first evidence of a demonstrative spatial repellent protective efficacy in reducing risk of malaria infection in an African setting characterised by high malaria transmission, pyrethroid resistant malaria vectors, and high coverage of insecticide treated nets.”
AbstractFind in source - supportedReviewer 2Results support spatial repellent products as a beneficial component of malaria prevention.The claim is supported by the significant reduction in malaria infection and the safety profile.Evidence: The trial demonstrated significant protective efficacy and no safety concerns.
“Results support spatial repellent products as a beneficial component of malaria prevention.”
AbstractFind in source
Efficacy claim is anchored to an adequate endpoint and a meaningful effect.
- ADEQUATESurrogate endpointThe primary endpoint is first-time malaria infection measured by microscopy, which is a clinical outcome (infection) rather than a surrogate biomarker. The trial directly measures malaria infection incidence, a hard clinical endpoint. Therefore, the efficacy claim is based on a clinical outcome, not a surrogate.
“The outcome of the primary endpoint indicated that spatial repellents significantly reduced the hazard rate of first-time malaria infection by 33·4% (95% CI 11·1–50·1; p=0·0058)”
- ADEQUATEEffect sizeThe reported protective efficacy of 33.4% (interim) and 32.7% (final) against first-time malaria infection is statistically significant and clinically meaningful, as it represents a substantial reduction in malaria incidence in a high-transmission setting. The effect size is anchored to a clinical outcome (infection) and is consistent with the pre-specified target of 30% reduction.
“The estimated protective efficacy of spatial repellents against first-time malaria infection relative to placebo from the intention-to-treat cohort population (cluster core areas) at the interim timepoint was 33·4% (95% two-sided CI 11·1–50·1; one-sided p=0·0029 and two-sided p=0·0058).”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
1 finding · worst mediumRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
- Data/code availability incompleteAssessed
The introduction cites prior evidence on spatial repellents, including trials in Peru, China, and Indonesia, and identifies the gap in evidence for Africa. The rationale linking the premise to the study objectives is explicit. Limitations of prior research (e.g., inconclusive outcomes, lack of African trials) are acknowledged and addressed by the study design.
“Evidence of an epidemiological effect of spatial repellents against vector-borne disease is limited to a single trial against dengue fever in Peru (protective effect of 34·1%) and another trial against malaria in China (protective effect of 77% by use of metofluthrin coils alone). A third trial in Indonesia indicated a reduction in malaria infection incidence by use of spatial repellents (protective effect of 27·7%), although not significant.”
“This trial, part of the Advancing Evidence for the Global Implementation of Spatial Repellents consortium, was designed to show and quantify protective efficacy of spatial repellents in reducing malaria infection incidence in Busia County, Kenya.”
“To meet this target, the global vector control response acknowledges the need for additional multidisciplinary vector control tools such as spatial repellents.”
“Evidence of an epidemiological effect of spatial repellents against vector-borne disease is limited to a single trial against dengue fever in Peru (protective effect of 34·1%) and another trial against malaria in China (protective effect of 77% by use of metofluthrin coils alone). A third trial in Indonesia indicated a reduction in malaria infection incidence by use of spatial repellents (protective effect of 27·7%), although not significant.”
“This trial, part of the Advancing Evidence for the Global Implementation of Spatial Repellents consortium, was designed to show and quantify protective efficacy of spatial repellents in reducing malaria infection incidence in Busia County, Kenya.”
Randomization was done by an external statistician using R, with masking of investigators, staff, and participants. A priori power analysis is detailed, specifying effect size, alpha, and power. Inclusion/exclusion criteria are pre-specified. The analysis population (ITT) and missing data handling are defined. The trial is registered and follows CONSORT guidelines.
“All randomisation was done by an external statistician using the sample function from RStudio 2021.09.0+351.pro6 (or R version 3.6.3). Investigators, staff, and study participants were masked to cluster allocation.”
“With assumptions of a baseline first-time infection HR of 3·0 per person-year and a between-cluster coefficient of variation of 48%, a total of 1056 events would be required to yield 80% power for establishing the primary hypothesis that spatial repellents reduce the first-time malaria HR compared with placebo at a 5% one-sided type-I error rate with a formal interim analysis done after 50% of the required total events were collected.”
“To be eligible for enrolment, participants needed to meet inclusion criteria of age (6 months to <10 years), having slept in the study clusters for more than 90% of nights each month, with no plans for extended travel exceeding 5 weeks outside the cluster, maintaining haemoglobin concentrations at greater than 5 g/dL, not participating in another clinical trial or being on regular malaria prophylaxis, and parents or guardians providing written consent.”
“All randomisation was done by an external statistician using the sample function from RStudio 2021.09.0+351.pro6 (or R version 3.6.3).”
“Investigators, staff, and study participants were masked to cluster allocation.”
“With assumptions of a baseline first-time infection HR of 3·0 per person-year and a between-cluster coefficient of variation of 48%, a total of 1056 events would be required to yield 80% power for establishing the primary hypothesis that spatial repellents reduce the first-time malaria HR compared with placebo at a 5% one-sided type-I error rate with a formal interim analysis done after 50% of the required total events were collected.”
Sex is reported and both sexes are enrolled, so sex_justified is not applicable. Age is reported with mean and range. Demographics include sex, age, and household characteristics. Species/strain and housing conditions are not applicable for a human trial.
“Age, years at enrolment, mean (SD); (min, max) | 5·5 (2·6); (1·1, 10·9) | 5·8 (2·6); (1·2, 10·9)”
“House wall type, mud, % | 78·9% | 82·4% | 78·9% | 82·4%”
“Age, years at enrolment, mean (SD); (min, max) | 5·5 (2·6); (1·1, 10·9) | 5·8 (2·6); (1·2, 10·9) | 5·5 (2·6); (1·1, 10·9) | 5·8 (2·6); (1·2, 10·9) | | Sex | | Male | 47·1% | 47·6% | 47·1% | 47·1% | | Female | 52·9% | 52·4% | 52·9% | 52·9%”
“maintaining haemoglobin concentrations at greater than 5 g/dL”
The study was approved by multiple named ethics committees with protocol numbers. Written informed consent was obtained from parents/guardians. Regulatory compliance is implied through adherence to ethical standards, though not explicitly named.
“The study protocol ( pp 6–49) was reviewed and approved by Kenya Medical Research Institute Scientific and Ethics Review Unit (protocol 3870, reference KEMRI/RES/7/3/1), Institutional Review Boards at Centers for Disease Control and Prevention (protocol number 7252), University of Notre Dame (protocol number 19-08-5506), and the WHO Ethical Review Committee (ERC.0003185).”
“Study staff obtained the written informed consent of parents or legal guardians of study participants for cohort participation, mosquito collectors conducting human landing catch (HLC) collections, and heads of households for product placement.”
“The study protocol ( pp 6–49) was reviewed and approved by Kenya Medical Research Institute Scientific and Ethics Review Unit (protocol 3870, reference KEMRI/RES/7/3/1), Institutional Review Boards at Centers for Disease Control and Prevention (protocol number 7252), University of Notre Dame (protocol number 19-08-5506), and the WHO Ethical Review Committee (ERC.0003185).”
“Study staff obtained the written informed consent of parents or legal guardians of study participants for cohort participation, mosquito collectors conducting human landing catch (HLC) collections, and heads of households for product placement.”
The investigational product (Mosquito Shield) is identified with manufacturer and application details. Statistical software is named with versions. No antibodies, cell lines, or mycoplasma testing are applicable. Organisms (mosquito vectors) are identified to species.
“Our intervention was a transfluthrin-based passive emanator (Mosquito Shield) designed and produced by SC Johnson & Son (Racine, WI, USA), as described previously.”
“Data analyses were done with SAS version 9.4 and RStudio 2023.12.0.”
“The main malaria vectors in this setting are Anopheles gambiae, Anopheles arabiensis and Anopheles funestus , all of which are resistant to multiple pyrethroid insecticides.”
“Our intervention was a transfluthrin-based passive emanator (Mosquito Shield) designed and produced by SC Johnson & Son (Racine, WI, USA), as described previously.”
“Data analyses were done with SAS version 9.4 and RStudio 2023.12.0.”
The primary analysis uses cloglog regression with random effects, and p-values are reported exactly. Effect sizes are reported with 95% CIs. Software is identified. Data presentation includes per-group n and incidence rates. Mathematical plausibility checks are not applicable due to large N and continuous outcomes.
“The complementary-log–log (cloglog) regression was used to model interval-censored time to event data (collected every 2 weeks) and estimate the hazard ratio between spatial repellent and placebo with a proportional hazard assumption.”
“The estimated protective efficacy of spatial repellents against first-time malaria infection relative to placebo from the intention-to-treat cohort population (cluster core areas) at the interim timepoint () was 33·4% (95% two-sided CI 11·1–50·1; one-sided p=0·0029 and two-sided p=0·0058).”
“The estimated protective efficacy of spatial repellents against first-time malaria infection relative to placebo from the intention-to-treat cohort population (cluster core areas) at the interim timepoint () was 33·4% (95% two-sided CI 11·1–50·1; one-sided p=0·0029 and two-sided p=0·0058).”
“The complementary-log–log (cloglog) regression was used to model interval-censored time to event data (collected every 2 weeks) and estimate the hazard ratio between spatial repellent and placebo with a proportional hazard assumption.”
“The estimated protective efficacy of spatial repellents against first-time malaria infection relative to placebo from the intention-to-treat cohort population (cluster core areas) at the interim timepoint () was 33·4% (95% two-sided CI 11·1–50·1; one-sided p=0·0029 and two-sided p=0·0058).”
The data availability statement says data will be made available on request to a specific email, but does not specify a repository, platform, or conditions. This is reported_but_inadequate. No repository deposit or accession numbers are provided. Code sharing is not mentioned.
“De-identified analytical datasets, including de-identified participant data, data dictionaries, and analytical codes, will be made available with publication on request to FL (at fang.liu.131@nd.edu ).”
“De-identified analytical datasets, including de-identified participant data, data dictionaries, and analytical codes, will be made available with publication on request to FL (at fang.liu.131@nd.edu ).”
The trial is registered with ClinicalTrials.gov. CONSORT guidelines are referenced. All outcomes are reported, including negative entomological results. Limitations are discussed. Conclusions are proportional. Funding and COI are declared.
“This trial is registered with ClinicalTrials.gov (https://ClinicalTrials.gov) , NCT04766879 (https://clinicaltrials.gov/ct2/show/NCT04766879) .”
“Detailed descriptions of study design, methods, and statistical analyses have been published previously and are reported following CONSORT guidelines ( pp 1–5).”
“There are several considerations regarding the lack of significant differences between spatial repellent and placebo for entomology endpoints. First, the study was not powered to detect significant effects of entomological endpoints due to the large number of clusters required, which was restrictive for study implementation.”
“This trial is registered with ClinicalTrials.gov (http://ClinicalTrials.gov) , NCT04766879 (https://clinicaltrials.gov/ct2/show/NCT04766879) and is complete.”
“Detailed descriptions of study design, methods, and statistical analyses have been published previously and are reported following CONSORT guidelines ( pp 1–5).”
Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.
Broken references and links
None found · partly checkedReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.
Checked 25 references by DOI: 17 verified — 8 no DOI (shown, not verified).
- NO DOIWorld malaria reportNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIGlobal vector control response 2017-2030No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIKenya Malaria Indicator Survey 2020No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIRegression analysis of grouped survival data with application to breast cancer dataNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDiscrete-time methods for the analysis of event historiesNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIA multiple testing procedure for clinical trialsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIStatistical analysis with missing dataNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOICommunitywide effects of permethrin-treated bed nets on child mortality and malaria morbidity in western KenyaNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
Copyediting
6 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 6 minor suggestions below.
6 copyedit issues flagged: mostly consistency, clarity, other.
- MINORconsistencyAbstract, Methods“A prospective, cluster-randomised, controlled trial in Busia County, western Kenya was done to quantify the efficacy of a transfluthrin-based spatial repellent against human malaria infection following mass distribution of insecticide treated nets.”→ Consider adding a comma after 'Kenya' for clarity.Minor punctuation.
- MINORclarityResults, paragraph 3“The estimated protective efficacy of spatial repellents against first-time malaria infection relative to placebo from the intention-to-treat cohort population (cluster core areas) at the interim timepoint () was 33·4% (95% two-sided CI 11·1–50·1; one-sided p=0·0029 and two-sided p=0·0058).”→ The empty parentheses after 'timepoint' likely refer to a figure; ensure the figure reference is included.Missing figure reference.
- MINORconsistencyTable 1“Number of glass windows, mean (SD); (min, max) | 1·02 ± 1·84 (0, 13) | 0·81 ± 1·63 (0, 9) | 1·03 ± 1·85 (0, 13) | 0·82 ± 1·65 (0, 9)”→ Use consistent notation for mean (SD) across the table.Inconsistent use of ± vs (SD).
- MINORconsistencyAbstract, Methods“NCT04766879 (https://clinicaltrials.gov/ct2/show/NCT04766879)”→ Ensure consistent formatting of trial registration number and URL.The URL is repeated in the text; consider using a single reference.
- MINORclarityMethods, Statistical analysis“The study adopted a group sequential design with one formal preplanned interim analysis of the primary endpoint when 50% of the required events were collected.”→ Consider clarifying the timing of the interim analysis relative to the study timeline.The sentence is clear but could be more explicit about the calendar time.
- MINORotherResults, paragraph 3“The estimated protective efficacy of spatial repellents against first-time malaria infection relative to placebo from the intention-to-treat cohort population (cluster core areas) at the interim timepoint () was 33·4%”→ Remove the empty parentheses or insert the figure reference.There is an empty parenthesis after 'timepoint'.
The published work is robust and well-reported; an informed reader should weigh the limited data availability as a minor transparency gap. No erratum is warranted for the rigor dimensions, but the authors should consider improving data access for reproducibility.
- 1.HIGHdata codeIn the Data sharing section, replace the 'on request to FL' statement with a concrete repository deposit (e.g., Dryad, Zenodo) or a managed-access platform with conditions and a timeline.A vague data availability statement is a transparency gap that undermines reproducibility and is a common reviewer concern.
- 2.HIGHdata codeAdd a code sharing statement with a link to a version-controlled repository (e.g., GitHub) and a persistent identifier.The paper mentions analytical codes but does not provide a mechanism for access, which is essential for reproducibility.
- 3.MEDIUMcopyeditIn Results, paragraph 3, insert the missing figure reference in the empty parentheses after 'interim timepoint'.The empty parentheses are a clear copyedit error that should be fixed for clarity.
- 4.MEDIUMcopyeditIn Table 1, standardize the notation for mean (SD) to avoid mixing '±' and '(SD)'.Consistent notation improves readability and avoids confusion.
- 5.MEDIUMcopyeditIn the Abstract, add a comma after 'Kenya' for clarity.Minor punctuation fix for readability.
- 6.MEDIUMcopyeditIn the Abstract, ensure the trial registration URL is formatted consistently and not repeated unnecessarily.Consistent formatting of registration details is a minor polish item.
- 7.LOWethicsIn the Methods, explicitly name the regulatory framework (e.g., Declaration of Helsinki, ICH-GCP) to strengthen the regulatory compliance statement.While implied, explicitly naming the framework would remove any ambiguity about regulatory compliance.
- 8.LOWotherIn Methods, Statistical analysis, clarify the calendar timing of the interim analysis relative to the study timeline.The sentence is clear but could be more explicit about when the interim analysis occurred.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.